Widegren Henrik, Korsgren Magnus, Andersson Morgan, Greiff Lennart
Department of Otorhinolaryngology, Head & Neck Surgery, Lund University Hospital, Lund, Sweden.
Respir Med. 2007 Sep;101(9):1982-7. doi: 10.1016/j.rmed.2007.04.005. Epub 2007 May 25.
TNFalpha is a cytokine that may contribute to the pathophysiology of airway inflammation. Inhalation of TNFalpha produces granulocyte recruitment and airway hyperresponsiveness in man. Anti-TNFalpha treatment may inhibit allergen-induced plasma exudation in guinea-pig airways. Increased nasal mucosal output of TNFalpha has been demonstrated in allergic rhinitis, but the effect of TNFalpha on the human nasal mucosa has not been examined in vivo.
To examine effects of topical TNFalpha on the human nasal mucosa in vivo.
In a dose-finding study, healthy subjects received intranasal TNFalpha (0-7.5 microg). Nasal lavages were carried out before as well as 10 min and 24 h post challenge and alpha(2)-macroglobulin was measured as an index of plasma exudation. In a second study, involving patients with allergic rhinitis examined out of season, a sham-controlled nasal challenge with TNFalpha (10 microg) was performed and followed 24 h later by an allergen challenge. Lavages were performed before the TNFalpha challenge, 24 h thereafter, and 10 min post allergen challenge. alpha(2)-Macroglobulin, eosinophil cationic protein (ECP), myeloperoxidase (MPO), and IL-8 were analyzed as indices of plasma exudation, eosinophil activity, neutrophil activity, and pro-inflammatory cytokine production, respectively.
In the dose-finding study, TNFalpha produced significant increases in alpha(2)-macroglobulin 24h post challenge (p<0.01). In allergic rhinitis, 10 microg of TNFalpha also produced this effect (p<0.01) as well as increases in ECP and IL-8 (p<0.01). MPO was increased 24 h post challenge, but this change did not reach statistical significance. TNFalpha did not produce any acute effects and did not affect the responsiveness to allergen.
The present study demonstrates that topical TNFalpha produces a human nasal inflammatory response. These data suggest a role of TNFalpha in nasal conditions characterized by mucosal inflammation.
肿瘤坏死因子α(TNFα)是一种细胞因子,可能参与气道炎症的病理生理过程。吸入TNFα可导致人体粒细胞募集和气道高反应性。抗TNFα治疗可能抑制豚鼠气道中变应原诱导的血浆渗出。变应性鼻炎患者鼻黏膜TNFα分泌增加已得到证实,但TNFα对人体鼻黏膜的影响尚未在体内进行研究。
研究局部应用TNFα对人体鼻黏膜的体内作用。
在一项剂量探索研究中,健康受试者接受鼻内注射TNFα(0 - 7.5微克)。在激发前以及激发后10分钟和24小时进行鼻腔灌洗,并检测α2 -巨球蛋白作为血浆渗出的指标。在第二项研究中,纳入非发病季节的变应性鼻炎患者,进行假对照的TNFα(10微克)鼻腔激发,24小时后再进行变应原激发。在TNFα激发前、激发后24小时以及变应原激发后10分钟进行灌洗。分别分析α2 -巨球蛋白、嗜酸性粒细胞阳离子蛋白(ECP)、髓过氧化物酶(MPO)和白细胞介素-8作为血浆渗出、嗜酸性粒细胞活性、中性粒细胞活性和促炎细胞因子产生的指标。
在剂量探索研究中,TNFα在激发后24小时使α2 -巨球蛋白显著增加(p<0.01)。在变应性鼻炎中,10微克的TNFα也产生了这种效应(p<0.01),同时ECP和白细胞介素-8增加(p<0.01)。MPO在激发后24小时增加,但这种变化未达到统计学意义。TNFα未产生任何急性效应,也不影响对变应原的反应性。
本研究表明局部应用TNFα可引起人体鼻黏膜炎症反应。这些数据提示TNFα在以黏膜炎症为特征的鼻部疾病中起作用。